…
Elevation Oncology, Inc., an oncology company, focuses on the discovery and development of cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs. The company's lead candidate is EO-3021, an antibody-drug conjugate designed to target Claudin 18.2, a clinically validated molecular target. Its EO-3021 selectively delivers a cytotoxic payload directly to cancer cells expressing Claudin 18.2. Elevation Oncology, Inc. has a license agreement with CSPC Megalith Biopharmaceutical Co., Ltd. to develop and commercialize EO-3021. The company was formerly known as 14ner Oncology, Inc. and changed its name to Elevation Oncology, Inc. in February 2020. The company was incorporated in 2019 and is based in Boston, Massachusetts.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Income before tax | -95.06M | -32.04M | -17.27M | - |
| Net income | -95.08M | -32.04M | -17.27M | - |
| Selling general administrative | 15.83M | 8.45M | 1.80M | - |
| Reconciled depreciation | 0.03M | 0.02M | 0.01M | - |
| Ebit | -94.58M | -32.05M | -17.28M | -3.57M |
| Ebitda | -94.55M | -32.03M | -17.26M | - |
| Depreciation and amortization | 0.03M | 0.02M | 0.01M | - |
| Non operating income net other | -0.51M | - | - | - |
| Operating income | -94.55M | -32.05M | -17.28M | - |
| Other operating expenses | 94.55M | 32.05M | 17.28M | - |
| Interest expense | 0.48M | 0.01M | 0.00M | 0.00M |
| Tax provision | 0.03M | - | - | - |
| Income tax expense | 0.03M | -0.01M | -0.01M | - |
| Total revenue | 0.00M | 0.00M | 0.00M | - |
| Total operating expenses | 94.55M | 32.05M | 17.28M | - |
| Total other income expense net | -0.51M | 0.01M | 0.01M | - |
| Net income from continuing ops | -95.08M | -32.04M | -17.27M | - |
| Net income applicable to common shares | -95.08M | -32.04M | -17.27M | -8.82M |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 89.09M | 94.16M | 149.49M | 80.91M | 1.91M |
| Intangible assets | 0.00M | - | - | - | - |
| Other current assets | 4.86M | 2.70M | 3.14M | 1.39M | 0.17M |
| Total liab | 34.28M | 45.13M | 8.80M | 103.99M | 7.79M |
| Total stockholder equity | 54.81M | 49.03M | 140.70M | -23.08M | -5.87M |
| Other current liab | 3.64M | 9.33M | 3.14M | 1.11M | 0.14M |
| Common stock | 0.00M | 0.00M | 0.00M | - | - |
| Capital stock | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Retained earnings | -195.97M | -150.27M | -55.19M | -23.15M | -5.88M |
| Other liab | - | 0.00M | 0.01M | 0.01M | - |
| Other assets | 0.00M | 1.09M | 0.03M | 0.07M | - |
| Cash | 49.26M | 45.92M | 146.28M | 79.40M | 1.74M |
| Total current liabilities | 4.14M | 15.69M | 8.79M | 6.79M | 0.60M |
| Net debt | -19.12M | -16.48M | -146.28M | -79.40M | -1.74M |
| Short long term debt total | 30.14M | 29.43M | - | - | - |
| Other stockholder equity | 250.77M | 105.30M | 195.88M | 0.07M | 0.01M |
| Property plant equipment | - | 0.10M | 0.04M | - | - |
| Total current assets | 87.96M | 92.98M | 149.42M | 80.79M | 1.91M |
| Net tangible assets | - | 49.03M | 140.70M | -23.14M | -5.87M |
| Short term investments | 33.85M | 44.36M | - | - | - |
| Long term debt | 30.14M | 29.43M | - | - | - |
| Accounts payable | 0.51M | 6.36M | 5.65M | 5.68M | 0.46M |
| Accumulated other comprehensive income | 0.01M | -0.16M | -149.49M | -0.01M | - |
| Common stock total equity | - | 0.00M | - | - | - |
| Retained earnings total equity | - | -150.27M | - | - | - |
| Non currrent assets other | 1.07M | 1.09M | 0.03M | 0.07M | - |
| Non current assets total | 1.13M | 1.18M | 0.07M | 0.12M | 0.00M |
| Long term debt total | - | 29.43M | - | - | - |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Investments | -44.31M | -44.31M | -0.07M | -44.31M |
| Change to liabilities | 6.90M | -0.03M | 5.22M | 0.69M |
| Total cashflows from investing activities | -44.40M | -44.40M | -0.07M | -0.07M |
| Net borrowings | 29.53M | 30.00M | 30.00M | 30.00M |
| Total cash from financing activities | 29.51M | 97.05M | 90.03M | 10.79M |
| Change to operating activities | 5.58M | 0.31M | -0.32M | -0.06M |
| Net income | -95.08M | -32.04M | -17.27M | -8.82M |
| Change in cash | -100.37M | 66.88M | 77.66M | 2.61M |
| Begin period cash flow | 146.28M | 79.40M | 1.74M | - |
| End period cash flow | 45.92M | 146.28M | 79.40M | 1.74M |
| Total cash from operating activities | -85.48M | -30.17M | -12.30M | -8.18M |
| Issuance of capital stock | 0.00M | 97.06M | 90.20M | - |
| Depreciation | 0.03M | 0.02M | 0.01M | 0.02M |
| Sale purchase of stock | -0.04M | - | - | - |
| Other cashflows from financing activities | 30.00M | -0.01M | 90.01M | -0.12M |
| Change to netincome | 3.49M | 1.57M | 0.05M | 0.01M |
| Capital expenditures | 0.09M | 0.09M | 0.07M | 0.07M |
| Cash flows other operating | -0.61M | - | - | - |
| Cash and cash equivalents changes | -100.37M | - | - | - |
| Change in working capital | 6.29M | 0.28M | 4.90M | - |
| Stock based compensation | 3.21M | 1.57M | 0.05M | - |
| Other non cash items | 0.07M | -66.35M | - | - |
| Free cash flow | -85.57M | -30.17M | -12.37M | - |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|
| NVO Novo Nordisk A/S |
-1.06 2.73% |
37.81 | 41.58 | 31.15 | 2.13 | 32.99 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
-5.64 1.08% |
515.02 | 30.22 | 24.27 | 10.36 | 6.50 | 24.66 |
| REGN Regeneron Pharmaceuticals Inc |
- -% |
920.69 | 29.07 | 20.12 | 7.57 | 3.82 | 19.42 |
| ARGNF argenx SE |
- -% |
965.00 | 45.77 | 31.25 | 13.84 | 7.12 | 36.06 |
Elevation Oncology, Inc., an oncology company, focuses on the discovery and development of cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs. The company's lead candidate is EO-3021, an antibody-drug conjugate designed to target Claudin 18.2, a clinically validated molecular target. Its EO-3021 selectively delivers a cytotoxic payload directly to cancer cells expressing Claudin 18.2. Elevation Oncology, Inc. has a license agreement with CSPC Megalith Biopharmaceutical Co., Ltd. to develop and commercialize EO-3021. The company was formerly known as 14ner Oncology, Inc. and changed its name to Elevation Oncology, Inc. in February 2020. The company was incorporated in 2019 and is based in Boston, Massachusetts.
| Name | Title | Year Born |
|---|---|---|
| Dr. Shawn M. Leland Pharm.D., R.Ph. | Founder, Pres, CEO & Director | 1984 |
| Mr. Joseph J. Ferra Jr. | Chief Financial Officer | 1976 |
| Ms. Valerie Malyvanh Jansen M.D., Ph.D. | Chief Medical Officer | 1978 |
| Ms. Tammy Furlong CPA, P.M.P. | VP of Fin. & Accounting and Sec. | NA |
| Dr. David Dornan Ph.D. | Chief Scientific Officer | 1978 |
| Candice Masse | Sr. Director of Corp. Communications & Investor Relations | NA |
| Mr. Robert C. Yang | VP of Legal Affairs | NA |
| Mr. Brian Sullivan | VP of Corp. Devel. | NA |
| Mr. Ryan Bloomer | Head of CMC | NA |
| Mr. Joseph J. Ferra Jr. | CEO, President & Director | 1975 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.